Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

---------------------- % HbA1c at baseline 7.67 7.90 7.45 7.38 -------------------------------------------------------------------------- % HbA1c at end of treatment 7.15 7.28 7.00 6.80 -------------------------------------------------------------------------- Change from baseline -0.54* -0.62* -0.45* -0.73* -------------------------------------------------------------------------- Mean change in weight (kg) -0.27 -0.28 -1.13 -3.09* -------------------------------------------------------------------------- *p = < 0.05

Although the treatment duration in the study was only 28 days, decreases in HbA1c and body weight were observed across all dose arms. Changes in HbA1c from baseline were statistically significant across all treatment arms. The most commonly reported adverse events were nausea and vomiting which were mostly mild, transient, dose dependent and limited to the first week of therapy.

"We've been very pleased with the positive results of this study and rapid progress in the ITCA 650 development program," said K. Alice Leung, President and CEO of Intarcia. "Within just 4 months of completing the phase 1b study, Intarcia began enrollment of an ongoing phase 2 study comparing ITCA 650 with twice-daily Byetta® (exenatide) injection among 150 patients with type 2 diabetes over a 3-month treatment period."

The phase 2 trial will evaluate ITCA 650 against the current standard of care for a longer duration of treatment and among a larger population of type 2 diabetes patients. The goals of the ITCA 650 program are to enhance the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, around-the-clock therapeutic drug levels, and to reduce side effects, including nausea associated with high peak levels of exenatide exposure observed with
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... Therapeutics,(Amex: CXM ) today reported financial results and highlights ... business strategies,for its three operating units: (1) InnerCool Therapies, (2) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), ... InnerCool Therapies, ...
... /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" ... on researching, developing, manufacturing and,marketing biopharmaceutical products, today ... ended September 30, 2008., Third Quarter ... increased 21.6% over the third quarter 2007 to ...
... 4:30 p.m. Eastern Time -, SAN FRANCISCO, Nov. ... on its corporate progress and financial,results for the quarter ... another quarter of significant,achievement and progress and was capped ... Dimebon. This collaboration not only gives us,access to a ...
Cached Biology Technology:Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 2Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 3Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 4Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 5Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 6Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 7Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 8Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 9Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 10Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 113SBio Inc. Announces Third Quarter 2008 Results 23SBio Inc. Announces Third Quarter 2008 Results 33SBio Inc. Announces Third Quarter 2008 Results 43SBio Inc. Announces Third Quarter 2008 Results 53SBio Inc. Announces Third Quarter 2008 Results 63SBio Inc. Announces Third Quarter 2008 Results 73SBio Inc. Announces Third Quarter 2008 Results 83SBio Inc. Announces Third Quarter 2008 Results 93SBio Inc. Announces Third Quarter 2008 Results 103SBio Inc. Announces Third Quarter 2008 Results 113SBio Inc. Announces Third Quarter 2008 Results 123SBio Inc. Announces Third Quarter 2008 Results 133SBio Inc. Announces Third Quarter 2008 Results 143SBio Inc. Announces Third Quarter 2008 Results 15Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... obesity in the United States is reaching epidemic proportions. With ... time television devoted to foods and beverages and continuing questions ... the November/December issue of the Journal of Nutrition Education ... might be a large contributor to the problem. Researchers ...
... laboratory that deciphered the DNA codes, or genomes, of the ... Genome 10K Project, an international effort to build an invaluable ... conducting comparative studies on a scale that currently can not ... in a paper published in the Nov. 5, 2009 issue ...
... VALLEY, Calif., Oct. 19 Spectros, developer and manufacturer ... light on life-threatening diseases, announced today that it has ... Tissue Oximeter and Sensors. The markets covered include ... Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and ...
Cached Biology News:TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
... Gel loading solution, ... for non-denaturing polyacrylamide and ... nucleic acids and offers ... tracking dyes (bromphenol blue ...
...
... PCR Optimization Kits without ammonium sulfate are ... PCR, such as Taq and AmpliThem™™ DNA ... of PCR systems in one experiment by ... primers into the PreMixes supplied with the ...
Biology Products: